At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Pegylated Irinotecandrug
Likely dose
Pegylated Irinotecan 145 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
In Brief
A Phase 2 clinical trial evaluating Pegylated Irinotecan for Stage IV Non-small Cell Lung Cancer (NSCLC) and 5 related conditions. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
CountriesUnited States
CollaboratorsNektar Therapeutics
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartAug 2015
Primary CompletionSep 2018
Study CompletionJul 2019
TodayJul 2026
First PostedDec 9, 2014
Enrollment StartAug 1, 2015
Primary CompletionSep 8, 2018
Study CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.6 years ago
Interventions
Pegylated Irinotecandrug
Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)